News
IOVA
10.17
-0.25%
-0.03
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
NASDAQ · 21h ago
Weekly Report: what happened at IOVA last week (0914-0918)?
Weekly Report · 1d ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Barchart · 3d ago
Iovance Biotherapeutics put buyer realizes 64% same-day gains
TipRanks · 4d ago
10 mid-cap healthcare stocks with the strongest momentum grades
Seeking Alpha · 4d ago
These mid-cap stocks have A+ momentum grades and over 100% YTD growth
Seeking Alpha · 5d ago
Iovance Biotherapeutics Is Maintained at Overweight by Barclays
Dow Jones · 5d ago
Barclays Maintains Overweight on Iovance Biotherapeutics, Raises Price Target to $15
Benzinga · 5d ago
Iovance Biotherapeutics price target raised to $15 from $13 at Barclays
TipRanks · 5d ago
Iovance Biotherapeutics (IOVA) Receives a Buy from Barclays
TipRanks · 5d ago
Biotech Stocks At 52-Week Highs - NUTX +8%, IOVA +7%, ATRC, CNC, CON
NASDAQ · 09/15 07:25
After Hours Most Active for Sep 14, 2026 : CMCSA, NVDA, AVGO, NOK, IOVA, CCC, NKE, PATH, JOBY, TSLL, ACHR, GIS
NASDAQ · 09/14 20:24
Weekly Report: what happened at IOVA last week (0907-0911)?
Weekly Report · 09/14 09:08
Weekly Report: what happened at IOVA last week (0831-0904)?
Weekly Report · 09/07 09:07
The best Quant-rated stocks trading below $10 right now
Seeking Alpha · 09/04 10:51
Iovance Biotherapeutics put volume heavy and directionally bearish
TipRanks · 09/03 14:55
Most shorted stocks on Wall Street
Seeking Alpha · 09/02 14:28
Mid-cap healthcare stocks ranked by quant ratings after earnings season
Seeking Alpha · 09/01 14:15
Weekly Report: what happened at IOVA last week (0824-0828)?
Weekly Report · 08/31 09:08
These ten healthcare stocks posted the biggest gains over the past month
Seeking Alpha · 08/28 11:54
More
Webull provides a variety of real-time IOVA stock news. You can receive the latest news about Iovance Biotherp through multiple platforms. This information may help you make smarter investment decisions.
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.